Huadong Medicine Future Growth
Future criteria checks 1/6
Huadong Medicine is forecast to grow earnings and revenue by 14.4% and 8.6% per annum respectively. EPS is expected to grow by 14.4% per annum. Return on equity is forecast to be 15.9% in 3 years.
Key information
14.4%
Earnings growth rate
14.4%
EPS growth rate
Healthcare earnings growth | 21.5% |
Revenue growth rate | 8.6% |
Future return on equity | 15.9% |
Analyst coverage | Good |
Last updated | 10 Jul 2024 |
Recent future growth updates
Recent updates
Earnings Working Against Huadong Medicine Co., Ltd's (SZSE:000963) Share Price
Aug 05Huadong Medicine (SZSE:000963) Seems To Use Debt Rather Sparingly
Jun 28There Are Reasons To Feel Uneasy About Huadong Medicine's (SZSE:000963) Returns On Capital
Jun 10Huadong Medicine Co., Ltd (SZSE:000963) Yearly Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Apr 21Market Cool On Huadong Medicine Co., Ltd's (SZSE:000963) Earnings
Apr 08Is Huadong Medicine (SZSE:000963) A Risky Investment?
Mar 16Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 52,597 | 4,428 | 3,427 | 4,875 | 11 |
12/31/2025 | 49,046 | 3,920 | 2,924 | 4,379 | 15 |
12/31/2024 | 44,973 | 3,307 | 2,259 | 3,427 | 15 |
3/31/2024 | 40,920 | 2,946 | 2,010 | 3,691 | N/A |
12/31/2023 | 40,624 | 2,839 | 2,323 | 3,929 | N/A |
9/30/2023 | 40,251 | 2,707 | 1,996 | 3,311 | N/A |
6/30/2023 | 39,902 | 2,592 | 2,932 | 4,119 | N/A |
3/31/2023 | 38,897 | 2,550 | 998 | 2,396 | N/A |
1/1/2023 | 37,715 | 2,499 | 1,189 | 2,382 | N/A |
9/30/2022 | 36,494 | 2,388 | 1,266 | 2,384 | N/A |
6/30/2022 | 35,582 | 2,342 | 696 | 1,715 | N/A |
3/31/2022 | 34,599 | 2,248 | 1,897 | 2,607 | N/A |
1/1/2022 | 34,563 | 2,302 | 2,351 | 3,170 | N/A |
9/30/2021 | 34,110 | 2,324 | 2,468 | 3,616 | N/A |
6/30/2021 | 34,202 | 2,389 | 2,540 | 3,894 | N/A |
3/31/2021 | 33,982 | 2,431 | 1,986 | 3,495 | N/A |
12/31/2020 | 33,683 | 2,820 | 1,938 | 3,411 | N/A |
9/30/2020 | 33,319 | 2,991 | 1,669 | 2,994 | N/A |
6/30/2020 | 33,858 | 2,948 | 1,036 | 2,294 | N/A |
3/31/2020 | 34,339 | 3,053 | 1,345 | 2,654 | N/A |
12/31/2019 | 35,446 | 2,813 | 648 | 2,002 | N/A |
9/30/2019 | 35,087 | 2,671 | 469 | 1,537 | N/A |
6/30/2019 | 33,587 | 2,570 | 878 | 1,932 | N/A |
3/31/2019 | 32,532 | 2,515 | 1,225 | 2,163 | N/A |
12/31/2018 | 30,663 | 2,267 | 1,163 | 2,039 | N/A |
9/30/2018 | 29,585 | 2,099 | 2,215 | 2,946 | N/A |
6/30/2018 | 29,066 | 2,031 | 1,822 | 2,455 | N/A |
3/31/2018 | 28,519 | 1,895 | 1,439 | 1,985 | N/A |
12/31/2017 | 27,832 | 1,780 | N/A | 1,661 | N/A |
9/30/2017 | 27,911 | 1,740 | N/A | 1,009 | N/A |
6/30/2017 | 27,227 | 1,665 | N/A | 612 | N/A |
3/31/2017 | 26,363 | 1,556 | N/A | 1,085 | N/A |
12/31/2016 | 25,380 | 1,447 | N/A | 1,347 | N/A |
9/30/2016 | 24,491 | 1,365 | N/A | 957 | N/A |
6/30/2016 | 23,588 | 1,253 | N/A | 796 | N/A |
3/31/2016 | 22,682 | 1,188 | N/A | 387 | N/A |
12/31/2015 | 21,727 | 1,097 | N/A | 659 | N/A |
9/30/2015 | 20,923 | 1,136 | N/A | 545 | N/A |
6/30/2015 | 20,220 | 1,034 | N/A | 1,144 | N/A |
3/31/2015 | 19,656 | 899 | N/A | 857 | N/A |
12/31/2014 | 18,947 | 757 | N/A | 741 | N/A |
9/30/2014 | 18,208 | 655 | N/A | 1,349 | N/A |
6/30/2014 | 17,724 | 631 | N/A | 624 | N/A |
3/31/2014 | 17,237 | 617 | N/A | 395 | N/A |
12/31/2013 | 16,718 | 575 | N/A | 477 | N/A |
9/30/2013 | 16,202 | 560 | N/A | -44 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 000963's forecast earnings growth (14.4% per year) is above the savings rate (2.9%).
Earnings vs Market: 000963's earnings (14.4% per year) are forecast to grow slower than the CN market (22% per year).
High Growth Earnings: 000963's earnings are forecast to grow, but not significantly.
Revenue vs Market: 000963's revenue (8.6% per year) is forecast to grow slower than the CN market (13.5% per year).
High Growth Revenue: 000963's revenue (8.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 000963's Return on Equity is forecast to be low in 3 years time (15.9%).